Health
Manochakian Calls for Repeat Genomic Testing Upon Osimertinib Progression in EGFR+ NSCLC – OncLive
Rami Manochakian, MD, discusses the role of osimertinib in patients with EGFR-mutated NSCLC, strategies for treatment following progression on the third-generation…
Because no standard approaches exist for patients with EGFR-mutated nonsmall cell lung cancer (NSCLC) who progress on standard frontline osimertinib (Tagrisso), repeat genomic testing should be done to identify potential resistance mechanisms that can help guide the next step in the treatment journey, Rami Manochakian, MD.
This is a very hot topic now. There are some potential rare, resistant mechanisms that could be a secondary actionable mutation such as MET amplification where you can potentially…
-
Noosa News23 hours agoHomicide investigation launched into stabbing death of 39-year-old Brisbane man at Bowen Hills apartment
-
General22 hours agoSector warns Coalition’s plan to limit overseas students ‘straight out of Trump’s playbook’
-
General22 hours agoDonald Trump and the ghost of Al Capone • Inside Story
-
General14 hours agoFrench far-right supporters rally against Le Pen conviction in Paris